ECSP066910A - Polimorfo cristalino de acetato de bazedoxifeno - Google Patents

Polimorfo cristalino de acetato de bazedoxifeno

Info

Publication number
ECSP066910A
ECSP066910A EC2006006910A ECSP066910A ECSP066910A EC SP066910 A ECSP066910 A EC SP066910A EC 2006006910 A EC2006006910 A EC 2006006910A EC SP066910 A ECSP066910 A EC SP066910A EC SP066910 A ECSP066910 A EC SP066910A
Authority
EC
Ecuador
Prior art keywords
crystal polymorph
acetate crystal
bazedoxifen acetate
bazedoxifen
polymorph
Prior art date
Application number
EC2006006910A
Other languages
English (en)
Inventor
Kadum Abdul Nabi Ali
Pietro Allegrini
Aldo Belli
Roberto Brescello
Vincenzo Cannata
Malama K Chibwe
Livius Cotarca
Shridhar G Gangolli
Carl E Longfellow
Giorgio Soriato
Massimo Verzini
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066910(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP066910A publication Critical patent/ECSP066910A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención está dirigida a un polimorfo cristalino de acetato de bazedoxifeno, composiciones que contienen el mismo, preparaciones del mismo y usos del mismo
EC2006006910A 2004-04-07 2006-10-06 Polimorfo cristalino de acetato de bazedoxifeno ECSP066910A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56058404P 2004-04-07 2004-04-07

Publications (1)

Publication Number Publication Date
ECSP066910A true ECSP066910A (es) 2006-12-20

Family

ID=34965585

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006910A ECSP066910A (es) 2004-04-07 2006-10-06 Polimorfo cristalino de acetato de bazedoxifeno

Country Status (20)

Country Link
US (1) US7683052B2 (es)
EP (1) EP1732889A1 (es)
JP (2) JP2007532548A (es)
KR (1) KR20070004815A (es)
CN (1) CN1938271A (es)
AR (1) AR048683A1 (es)
AU (1) AU2005233114A1 (es)
BR (1) BRPI0509257A (es)
CA (1) CA2561296A1 (es)
EC (1) ECSP066910A (es)
GT (1) GT200500080A (es)
IL (1) IL178101A0 (es)
NO (1) NO20065046L (es)
PA (1) PA8629201A1 (es)
PE (1) PE20060173A1 (es)
RU (1) RU2006132352A (es)
TW (1) TW200536845A (es)
UA (1) UA86055C2 (es)
WO (1) WO2005100314A1 (es)
ZA (1) ZA200608361B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070003623A1 (en) * 2005-06-29 2007-01-04 Wyeth Formulations of conjugated estrogens and bazedoxifene
CA2620174A1 (en) 2005-08-24 2007-03-01 Wyeth Bazedoxifene acetate formulations and manufacturing process thereof
PE20090100A1 (es) * 2007-03-30 2009-02-26 Wyeth Corp Metodos de separacion y deteccion de acetato de bacedoxifeno en composiciones farmaceuticas
CZ302358B6 (cs) * 2007-07-25 2011-03-30 Zentiva, A. S. Nové soli bazedoxifenu
CN101977897A (zh) * 2008-02-11 2011-02-16 惠氏有限责任公司 制备乙酸巴多昔芬的多晶型a的方法
US20100016290A1 (en) * 2008-02-11 2010-01-21 Livius Cotarca Amorphous polymorph of bazedoxifene acetate
ITMI20091109A1 (it) * 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
ES2436841T3 (es) 2009-10-27 2014-01-07 Wyeth Llc Formulaciones de bazedoxifeno con antioxidantes
EP2407467A1 (de) 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
WO2012007453A1 (en) 2010-07-14 2012-01-19 Sandoz Ag Crystalline compound of 1-[4-(2-azepan-1-ylethoxy)benzyl]-2-(4-hydroxyphenyl)-3-methyl-1h-indol-5-ol
US9212172B2 (en) 2010-09-14 2015-12-15 Dr. Reddy's Laboratories Limited Preparation of crystalline bazedoxifene and its salts
EP2471770A1 (en) 2010-12-28 2012-07-04 Sandoz Ag Method of preparing polymorphic pure form A of bazedoxifene acetate
CN103864664A (zh) * 2012-12-18 2014-06-18 江苏柯菲平医药有限公司 巴多昔芬乙酸盐新晶型及其制备方法
WO2014186325A1 (en) 2013-05-15 2014-11-20 Indiana University Research And Technology Corporation Processes and intermediates for preparing indole pharmaceuticals
CN103864665B (zh) * 2014-03-04 2016-03-02 苏州特瑞药业有限公司 醋酸巴多昔芬的制备方法
CN104030963A (zh) * 2014-06-30 2014-09-10 四川大学 一种巴多昔芬醋酸盐晶型a的制备方法
CN111004165A (zh) * 2019-12-03 2020-04-14 南京正济医药研究有限公司 一种醋酸巴多昔芬晶型a的制备方法
US11246874B1 (en) 2021-04-20 2022-02-15 Oxygen Biotech LLC Treatment of COVID-19

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
DE122009000061I1 (de) 1996-04-19 2009-12-31 Wyeth N D Ges D Staates Delawa Östrogene Verbindungen
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5780497A (en) * 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
SI1025077T1 (sl) 1997-10-15 2007-06-30 Wyeth Corp Novi ariloksi-alkil-dialkilamini
US6005102A (en) * 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
AR029538A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
IL165395A0 (en) * 2002-06-25 2006-01-15 Wyeth Corp Use of thio-oxubdile derivatives in treatment of hormone-related conditions
KR20060135866A (ko) 2004-04-07 2006-12-29 와이어쓰 바제독시펜 아세테이트의 결정질 다형체

Also Published As

Publication number Publication date
PE20060173A1 (es) 2006-04-12
AU2005233114A1 (en) 2005-10-27
KR20070004815A (ko) 2007-01-09
BRPI0509257A (pt) 2007-09-11
RU2006132352A (ru) 2008-05-20
GT200500080A (es) 2005-10-31
WO2005100314A1 (en) 2005-10-27
ZA200608361B (en) 2010-03-31
JP2007532548A (ja) 2007-11-15
UA86055C2 (ru) 2009-03-25
US7683052B2 (en) 2010-03-23
CA2561296A1 (en) 2005-10-27
US20050250762A1 (en) 2005-11-10
CN1938271A (zh) 2007-03-28
NO20065046L (no) 2006-11-06
EP1732889A1 (en) 2006-12-20
IL178101A0 (en) 2006-12-31
PA8629201A1 (es) 2005-11-25
JP2009007361A (ja) 2009-01-15
AR048683A1 (es) 2006-05-17
TW200536845A (en) 2005-11-16

Similar Documents

Publication Publication Date Title
ECSP066911A (es) Polimorfo cristalino de un acetato de bazedoxifeno
ECSP066910A (es) Polimorfo cristalino de acetato de bazedoxifeno
ECSP066912A (es) Formulaciones de dispersiones sólidas de acetato de bazedoxifeno
ECSP088214A (es) Formulaciones de acetato de bazedoxifeno que tienen una conversión polimórfica reducida
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
CL2004001602A1 (es) Compuestos no esteroidales derivados de propionanilida, moduladores del receptor androgenico con selectividad tisular (sarm); composicion farmaceutica; y uso en el tratamiento o prevencion de condiciones dependientes del receptor androgenico, como hi
NO20090295L (no) Substituerte heteroarylderivater
TW200738741A (en) Antiviral compounds
TW200738742A (en) Antiviral compounds
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
TW200628161A (en) Novel betulin derivatives, preparation thereof and use thereof
BRPI0411528A (pt) uso de isomalte como prebiótico
RS51970B (en) TRICYCLIC UNITS AND THEIR USE AS MODULATORS OF GLUCOCORTICOID RECEPTORS
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
ECSP067120A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
MX2009007104A (es) Derivados de oxindol sustituido y su uso como ligandos del receptor de vasopresina.
EA201170703A1 (ru) Производные адамантилбензамида
ATE445593T1 (de) Acetylenderivate
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
ECSP109961A (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica
SG158091A1 (en) Imidazoazepinone compounds
EA200602049A1 (ru) Пролекарства стероидов с андрогенным действием
UA85703C2 (en) Crystalline polymorph of bazedoxifene acetate
ECSP099679A (es) Nuevos compuestos y sus usos 707